Vanda Pharmaceuticals Inc VNDA
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2006-04-12 |
| Shares Out. | 60,140,000 |
| Website | vandapharma.com/ ↗ |
| Phone | 12027343400 |
| Employees | 533 |
| Revenue | $51.7M |
| Gross Profit | $46.6M |
| Net Income | -$48.6M |
| Free Cash Flow | -$127.3M |
| Total Assets | $433.5M |
| Total Liabilities | $152.8M |
| Equity | $280.8M |
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Vanda Pharmaceuticals Inc is a publicly traded company under the ticker symbol VNDA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)